Article: Valrubicin

Valrubicin
Systematic (IUPAC) name
[2-oxo-2-[2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl]oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl]pentanoate
Identifiers
CAS number	56124-62-0
ATC code	L01DB09
PubChem	41744
DrugBank	APRD00662
Chemical data
Formula	C34H36F3NO13
Mol. weight	723.644 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	>99%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

Dosage

800 mg weekly for 6 weeks

Side effects

• Blood in urine
• Incontinence
• painful or difficult urination
• Unusually frequent urination

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.